Core Viewpoint - Zhejiang Borui Biopharmaceutical Co., Ltd. (referred to as "Borui Biopharma") has submitted an IPO application, aiming to become a leader in the global immunology field, although it faces challenges in innovation and internationalization [1][5]. Company Overview - Borui Biopharma was incubated by the established pharmaceutical company Haizheng Pharmaceutical and restructured into a limited company in January 2019 [1]. - The company is primarily known for its product Adalimumab (brand name: Anjianing®), which has become the best-selling biosimilar in China, despite being a later entrant compared to competitors [3][5]. Financial Performance - In 2023, Anjianing® generated approximately 800 million yuan in sales, contributing about 70% of Borui's revenue, although this percentage is expected to decrease to around 50% in 2024 and 2025 [5][6]. - The sales figures for Anjianing® from 2021 to 2025 show a decline from 1.54 billion yuan in 2023 to an estimated 1.22 billion yuan in 2025 [4][6]. - Borui's other biosimilars, such as Trastuzumab (Anruize®), are also performing well, with sales expected to double to 200 million yuan in 2024 [5]. Market Position - Borui Biopharma has ranked first in sales of autoimmune biological agents in China for two consecutive years, with over 20 products in the pipeline [7]. - The company is facing challenges due to potential price reductions from healthcare negotiations and the impact of biosimilar procurement policies [7][9]. Innovation and Future Prospects - Borui's first innovative drug, Zebeituo (Anruixi®), was approved in 2023 and is expected to see significant sales growth, reaching approximately 3-4 billion yuan in 2025 [10][11]. - The company is also developing antibody-drug conjugates (ADCs) and aims to strengthen its innovative drug portfolio, although these products are still in early stages [11][12]. - The appointment of a new CEO, Liu Min, is seen as a strategic move to enhance innovation and international business expansion [12].